I Vaz-Luis1, E P Winer2, N U Lin3. 1. Department of Medical Oncology, Breast Oncology Center, Dana-Farber Cancer Institute, Boston, USA; Clinical and Translational Oncology Research Unit, Instituto de Medicina Molecular, Lisbon, Portugal. 2. Department of Medical Oncology, Breast Oncology Center, Dana-Farber Cancer Institute, Boston, USA. 3. Department of Medical Oncology, Breast Oncology Center, Dana-Farber Cancer Institute, Boston, USA. Electronic address: nancy_lin@dfci.harvard.edu.
Abstract
BACKGROUND: Human epidermal growth factor receptor-2 (HER2) overexpression occurs in ∼20% of breast cancers and has historically been associated with decreased survival. Despite substantial improvements in clinical outcomes, particularly with the emergence of HER2-targeted therapy, a substantial minority of patients still relapses, and progression is inevitable in metastatic disease. Accumulating data indicate that HER2-positive disease is itself a heterogeneous entity. METHODS AND RESULTS: In this article, we qualitatively review the data supporting the classification of HER2-positive disease as at least two separate entities, distinguished by estrogen receptor (ER) status. We summarize differences in clinical outcomes, including response to neoadjuvant therapy, timing and patterns of dissemination, efficacy of therapy in the metastatic setting and survival outcomes. CONCLUSIONS: The collective data are sufficiently strong at this point to propose that ER status defines two distinct subtypes within HER2-positive breast cancer, and we highlight the implications of this knowledge in future research, including understanding of the basic biology of HER2-positive breast cancer and the design of future clinical trials.
BACKGROUND:Human epidermal growth factor receptor-2 (HER2) overexpression occurs in ∼20% of breast cancers and has historically been associated with decreased survival. Despite substantial improvements in clinical outcomes, particularly with the emergence of HER2-targeted therapy, a substantial minority of patients still relapses, and progression is inevitable in metastatic disease. Accumulating data indicate that HER2-positive disease is itself a heterogeneous entity. METHODS AND RESULTS: In this article, we qualitatively review the data supporting the classification of HER2-positive disease as at least two separate entities, distinguished by estrogen receptor (ER) status. We summarize differences in clinical outcomes, including response to neoadjuvant therapy, timing and patterns of dissemination, efficacy of therapy in the metastatic setting and survival outcomes. CONCLUSIONS: The collective data are sufficiently strong at this point to propose that ER status defines two distinct subtypes within HER2-positive breast cancer, and we highlight the implications of this knowledge in future research, including understanding of the basic biology of HER2-positive breast cancer and the design of future clinical trials.
Authors: Gunter von Minckwitz; Kathrin Schwedler; Marcus Schmidt; Jana Barinoff; Christoph Mundhenke; Tanja Cufer; Eduard Maartense; Felix E de Jongh; Klaus H Baumann; Joachim Bischoff; Nadia Harbeck; Hans-Joachim Lück; Nicolai Maass; Christoph Zielinski; Michael Andersson; Robert C Stein; Valentina Nekljudova; Sibylle Loibl Journal: Eur J Cancer Date: 2011-07-07 Impact factor: 9.162
Authors: Rong Hu; Shaheenah Dawood; Michelle D Holmes; Laura C Collins; Stuart J Schnitt; Kimberley Cole; Jonathan D Marotti; Susan E Hankinson; Graham A Colditz; Rulla M Tamimi Journal: Clin Cancer Res Date: 2011-02-15 Impact factor: 12.531
Authors: José Baselga; Karen A Gelmon; Shailendra Verma; Andrew Wardley; Pierfranco Conte; David Miles; Giulia Bianchi; Javier Cortes; Virginia A McNally; Graham A Ross; Pierre Fumoleau; Luca Gianni Journal: J Clin Oncol Date: 2010-02-01 Impact factor: 44.544
Authors: C Marchiò; R Natrajan; K K Shiu; M B K Lambros; S M Rodriguez-Pinilla; D S P Tan; C J Lord; D Hungermann; K Fenwick; N Tamber; A Mackay; J Palacios; A Sapino; H Buerger; A Ashworth; J S Reis-Filho Journal: J Pathol Date: 2008-12 Impact factor: 7.996
Authors: M Untch; R D Gelber; C Jackisch; M Procter; J Baselga; R Bell; D Cameron; M Bari; I Smith; B Leyland-Jones; E de Azambuja; P Wermuth; R Khasanov; F Feng-Yi; C Constantin; J I Mayordomo; C-H Su; S-Y Yu; A Lluch; E Senkus-Konefka; C Price; F Haslbauer; T Suarez Sahui; V Srimuninnimit; M Colleoni; A S Coates; M J Piccart-Gebhart; A Goldhirsch Journal: Ann Oncol Date: 2008-02-21 Impact factor: 32.976
Authors: Andrew M Wardley; Xavier Pivot; Flavia Morales-Vasquez; Luis M Zetina; Maria de Fátima Dias Gaui; Douglas Otero Reyes; Jacek Jassem; Claire Barton; Peter Button; Veronica Hersberger; Antonio Antón Torres Journal: J Clin Oncol Date: 2009-12-28 Impact factor: 44.544
Authors: Libero Santarpia; Takayuki Iwamoto; Angelo Di Leo; Naoki Hayashi; Giulia Bottai; Martha Stampfer; Fabrice André; Nicholas C Turner; W Fraser Symmans; Gabriel N Hortobágyi; Lajos Pusztai; Giampaolo Bianchini Journal: Oncologist Date: 2013-09-26
Authors: Ines Vaz-Luis; Davinia Seah; Erin M Olson; Nikhil Wagle; Otto Metzger-Filho; Jessica Sohl; Georgia Litsas; Harold J Burstein; Ian E Krop; Eric P Winer; Nancy U Lin Journal: Clin Breast Cancer Date: 2013-08 Impact factor: 3.225
Authors: Jamunarani Veeraraghavan; Carmine De Angelis; Jorge S Reis-Filho; Tomás Pascual; Aleix Prat; Mothaffar F Rimawi; C Kent Osborne; Rachel Schiff Journal: Breast Date: 2017-07-04 Impact factor: 4.380
Authors: Renata Duchnowska; Jacek Jassem; Chirayu Pankaj Goswami; Murat Dundar; Yesim Gökmen-Polar; Lang Li; Stephan Woditschka; Wojciech Biernat; Katarzyna Sosińska-Mielcarek; Bogumiła Czartoryska-Arłukowicz; Barbara Radecka; Zorica Tomasevic; Piotr Stępniak; Konrad Wojdan; George W Sledge; Patricia S Steeg; Sunil Badve Journal: J Neurooncol Date: 2015-01-06 Impact factor: 4.130
Authors: Elizabeth Scarr; Mark J Millan; Sabine Bahn; Alessandro Bertolino; Christoph W Turck; Shitij Kapur; Hans-Jürgen Möller; Brian Dean Journal: Int J Neuropsychopharmacol Date: 2015-04-21 Impact factor: 5.176
Authors: Dhiego Chaves de Almeida Bastos; Marcos Vinicius Calfat Maldaun; Raymond Sawaya; Dima Suki; Frederick F Lang; Paul D Brown; Ganesh Rao; Jeffrey S Weinberg; Sujit S Prabhu Journal: Neurooncol Pract Date: 2017-12-23